The Systemic Sclerosis (Scleroderma) drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Sclerosis (Scleroderma). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued products.
GlobalData tracks 109 drugs in development for Systemic Sclerosis (Scleroderma) by 104 companies/universities/institutes. The top development phase for Systemic Sclerosis (Scleroderma) is preclinical with 50 drugs in that stage. The Systemic Sclerosis (Scleroderma) pipeline has 101 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Systemic Sclerosis (Scleroderma) pipeline products market are: Genentech USA, Boehringer Ingelheim International and Coya Therapeutics.
The key targets in the Systemic Sclerosis (Scleroderma) pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39), and Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A).
The key mechanisms of action in the Systemic Sclerosis (Scleroderma) pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with six drugs in Phase III. The Systemic Sclerosis (Scleroderma) pipeline products include 12 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Systemic Sclerosis (Scleroderma) pipeline products market including Small Molecule, and Monoclonal Antibody.
Systemic Sclerosis (Scleroderma) overview
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants.
For a complete picture of Systemic Sclerosis (Scleroderma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
